{'fraction_non_alphanumeric': 0.018739352640545145, 'fraction_numerical': 0.013628620102214651, 'mean_word_length': 5.061855670103093, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

The K65R mutation has been reported to be associated with the use of abacavir, didanosine and tenofovir. With the advent of tenofovir we have assessed the change in the prevalence of this mutation. The prevalence of the K65R mutation remains low, but has significantly increased over a 2-year period. Although not associated with a specific drug, it is associated with the dual use of tenofovir, didanosine and the triple combination of tenofovir, didanosine and abacavir.